Oxford Biomedica Plc: Oxford Biomedica Plc announces Prelim Phase II Results
6th Oct 2005, 11:18 GMT
OXFORD, UK (MARKET WIRE)
Oxford Biomedica Plc: Oxford Biomedica Plc announces Prelim Phase II Results related news:
- Oxford Biomedica Plc announces Prelim Phase II Results — ArriveNet : Health
- Oxford BioMedica's posts positive cancer drug results — Pharmaceutical Business Review Online
- Lumen Therapeutics Announces Completion of the Phase I Trial and Phase II Development Plans for Lt-1951 - a Potential Treatment for Prevention of Coronary Artery Bypass Graft Failure — Surgery News from StratCenter.com
- ADVENTRX Reports Phase II CoFactor Trial Update — Pharmaceuticals News from StratCenter.com
- STAR launches Phase II of "Music in the Park" Series — Bollywood News
- Synthetic Blood to Accelerate Phase II Clinical Development of Oxycyte — Financial News News from StratCenter.com
- Oxford Industries Announces Record First Quarter Fiscal 2006 Results — PR Newswire: All Releases
- Novartis: FTY720 Phase II 12-month Data Show Sustained Benefits and Good Tolerability in Patients with Relapsing Multiple Sclerosis — ArriveNet : Press Releases
- Ciphergen, University College of London, and UCL BioMedica Plc. Sign Collaboration Agreement to Validate and Discover New Biomarkers for Breast and Ovarian Cancer — PR Newswire: All Releases
- Cytogen Announces Presentation of Data from Phase II Study Evaluating Combination of QUADRAMET(R) with Chemotherapy in Hormone Refractory Prostate Cancer — PR Newswire: All Releases
Latest news from Market Wire - Pharmaceuticals and Biotech:
- Qiagen N.V.: QIAGEN Introduces Novel Technology for Customized RNAi Assay Products
- IBEX TECHNOLOGIES INC.: IBEX: Analysis of Urinary C2C Distinguishes Between Individuals with Painful Knees and Individuals Identified by MRI to Have Early Osteoarthritis
- Daiichi Sankyo, Inc.: First Study to Evaluate WelChol/Ezetimibe and Simvastatin Effect on LDL-C Finds Additional Lipid Parameter Benefits
- Daiichi Sankyo, Inc.: WelChol and Ezetimibe Combination Therapy Provides Significant LDL-C Reductions
- Targeted Genetics Corporation: Interim Data on Use of tgAAC94 in the Treatment of Inflammatory Arthritis Presented at the American College of Rheumatology Meeting
- Crucell N.V.: Crucell Announces Third Quarter 2006 Results
- Acambis PLC: Acambis PLC announces Update on US MVA procurement
- SkyePharma PLC: SkyePharma PLC announces Board Appointment
- Base Technologies, Inc.: Base Technologies Award of Air Force Surgeon General Contract Continues Rapid Growth Trend
- Eugene Science, Inc.: Eugene Science Signs Major Distribution Agreement With RexGene Biotech